Munni Selagamsetty, MD
Internal Medicine · Colorado Springs, CONPI 1588621072
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Amgen at 52.9% of the total. Reporting peaked in 2023 at $13,345 and has fallen 59.9% since, to $5,354 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 878 payments — averaging $62.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$29K
- AstraZeneca$7K
- Sanofi-aventis U.S. LLC$6K
- AbbVie$2K
- Novo Nordisk$2K
- Novartis$1K
- plus $9K from 54 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1K
What the payments were for
- Consulting fees$11,69321%
- Speaking & faculty fees$22,20040%
- Travel & lodging$1,3933%
- Food & beverage$19,76336%
- Education$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,166 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 11 | $443,739 |
| JardianceEmpagliflozin | 40 | $65,253 |
| OzempicSemaglutide | 29 | $51,982 |
| FarxigaDapagliflozin Propanediol | 34 | $50,727 |
| MounjaroTirzepatide | 25 | $35,462 |
| EliquisApixaban | 22 | $26,359 |
| VascepaIcosapent Ethyl | 31 | $25,527 |
| JanuviaSitagliptin Phosphate | 11 | $17,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $15,923 |
| TrulicityDulaglutide | 11 | $12,200 |
| Repatha SureclickEvolocumab | 11 | $11,744 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $4,032 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 137 | $2,774 |
| Ezetimibe | 95 | $2,725 |
| Rosuvastatin Calcium | 125 | $2,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $454 | $443,73911 claims |
| Boehringer IngelheimJardiance | $918 | $65,25340 claims |
| Novo NordiskOzempic | $1,500 | $51,98229 claims |
| AstraZenecaFarxiga | $6,843 | $50,72734 claims |
| Lilly USA, LLCMounjaro, Trulicity | $862 | $47,66236 claims |
| PfizerEliquis | $515 | $26,35922 claims |
| MerckJanuvia | $211 | $17,28711 claims |
| GSKTrelegy Ellipta | $141 | $15,92316 claims |
| AbbVieArmour Thyroid | $1,598 | $83113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Colorado Springs
- Luke WebbColorado Springs$287K
- Samuel PiedadColorado Springs$154K
- Sridhar ReddyColorado Springs$21K
- Quinn HalversonColorado Springs$11K
- Pankaj NashikkarColorado Springs$10K
- Elizabeth CruzColorado Springs$9K
- Tayler SandersColorado Springs$7K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.